Jul 12, 2021 / 02:00PM GMT
Michael Thyring Engsig - Vaccibody AS - CEO
So good afternoon and good morning to our guests and listeners from the U.S. I'm Michael Engsig, CEO of Vaccibody, and I'm very much looking forward to take you through what we consider to be a very important next step in building the leading vaccine technology company.
Before I introduce my co-presenters today, I just want to take you through a couple of housekeeping issues. First of all, the forward-looking statements, I assume you are all familiar with those. And on that basis, we'll quickly move forward. You are also very welcome to send in questions via the function on the link on the web page you're looking at right now, and we'll be addressing these towards the end of this presentation.
If we go to Slide 3, I am very excited to have with me today Agnete Fredriksen, Co-Founder and Chief Innovation and Strategy Officer of Vaccibody; Mikkel Pedersen, Chief Scientific Officer of Vaccibody; Siri Torhaug, Chief Medical Officer of Vaccibody; and from Adaptive Biotechnologies, Harlan Robins, Co-Founder and Chief Scientific Officer.
If
Vaccibody AS Call to Discuss License Agreement with Adaptive Biotechnologies Corp Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers